Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic…
Wesana Announces First Quarter 2022 Financial Results May 31, 2022 17:30 ET | Source: www.wesanahealth.com. Investor Relations: Keenan Gentry Email: IR@wesanahealth.com Phone:…
Wesana Health Outlines Accelerated Drug Development Pathway May 10, 2022 07:30 ET CHICAGO and TORONTO, May 10, 2022 (GLOBE NEWSWIRE)…
CHICAGO and TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven…
CHICAGO and TORONTO, March 29, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF),…
CHICAGO and TORONTO, March 22, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF),…
Psychedelic Stock Watch
Pre-IND Meeting is a Significant Milestone in the Clinical Development of SANA-013, Defining the Pathway to Initiate in-Human Clinical Trials…
Naperville clinic to open Spring 2022 CHICAGO and TORONTO, March 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana”…
Forbes
Wesana’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen…
The meeting is scheduled for March 11, 2022 CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana”…
